'A Watershed Moment': GLP-1 Drug Succeeds in Late-Stage MASH Trial

(MedPage Today) -- Semaglutide (Wegovy) improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) and led to greater rates of MASH resolution, an interim analysis of a phase III trial showed.
In part 1 of...